Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Analysts Impressed As Novo Nordisk’s PIONEER 6 Trial Confirms Safety Profile Of Oral Semaglutide

Wed, 06/12/2019 - 8:39am

Oral semaglutide hit its main endpoint by demonstrating cardiovascular safety in people with type 2 diabetes and established cardiovascular disease...

      Related Stories 

USAID Reviewing India Financing Effort With Troubled DHFL

Wed, 06/12/2019 - 1:49am

The US Agency for International Development (USAID) is monitoring its Indian healthcare financing initiative with Dewan Housing Finance Corporation amid...

      Related Stories 

How Can Korea Grab Window Of Opportunity In AI Drug Development?

Tue, 06/11/2019 - 6:31pm

Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support...

      Related Stories 

Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

Tue, 06/11/2019 - 3:01pm

Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance,"...

      Related Stories 

Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL

Tue, 06/11/2019 - 12:34pm

The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a...

      Related Stories 

Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?

Tue, 06/11/2019 - 7:54am

Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II...

      Related Stories 

Xenikos Set To Start Phase III For Acute GVHD Drug

Tue, 06/11/2019 - 7:12am

The Dutch biotech's CEO tells Scrip that one-week treatment with T-Guard could change the paradigm for tackling steroid-refractory graft-versus-host disease.

      Related Stories 

Aurobindo Upbeat On Outlook As It Moves To Close Sandoz Deal

Mon, 06/10/2019 - 10:13pm

India's Aurobindo says it is betting its $1bn purchase of Sandoz' US dermatology assets will help “really fuel growth” and...

      Related Stories 

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

Mon, 06/10/2019 - 2:27pm

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and...

      Related Stories 

Questions Persist On Lilly’s Tirzepatide And Tolerability

Mon, 06/10/2019 - 1:36pm

Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly...

      Related Stories 

Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One

Mon, 06/10/2019 - 1:31pm

At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity...

      Related Stories 

CHART/TABLE: Pipeline Watch: ASCO Meeting Dominates Trial Updates

Mon, 06/10/2019 - 9:55am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics

Mon, 06/10/2019 - 8:36am

AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in...

      Related Stories 

Pages